Harnessing the epigenome to boost immunotherapy response in non-small cell lung cancer patients

The introduction of immune checkpoint inhibitor (ICI)-based therapy for non-oncogene addicted non-small cell lung cancer (NSCLC) has significantly transformed the treatment landscape of the disease. Inhibitors of the programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) immune check...

Descripción completa

Detalles Bibliográficos
Autores principales: Gkountakos, Anastasios, Delfino, Pietro, Lawlor, Rita T., Scarpa, Aldo, Corbo, Vincenzo, Bria, Emilio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Immunotherapy for Lung Cancer: Progress, Opportunities and Challenges
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8161860/
https://www.ncbi.nlm.nih.gov/pubmed/34104224
http://dx.doi.org/10.1177/17588359211006947

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8161860/
https://www.ncbi.nlm.nih.gov/pubmed/34104224
http://dx.doi.org/10.1177/17588359211006947

Ejemplares similares